News - Page 12 of 69 - Yokohama City University

2023-04-19

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-sided Metastatic Colorectal Cancer A Randomized Clinical Trial

Question : Among patients with RAS wild-type, left-sided metastatic colorectal cancer, does adding panitumumab (an anti–epidermal growth factor receptor monoclonal antibody) vs bevacizumab (an anti–vascular endothelial growth factor monoclonal antibody) to standard first-line chemotherapy improve overall survival?

2023-04-19

Genome-wide identification of tandem repeats associated with splicing variation across 49 tissues in humans

Tandem repeats (TRs) are one of the largest sources of polymorphism, and their length is associated with gene regulation. Although previous studies reported several tandem repeats regulating gene splicing in cis (spl-TRs), no large-scale study has been conducted. In this study, we established a genome-wide catalog of 9537 spl-TRs with a total of 58,290 significant TR–splicing associations across 49 tissues (false discovery rate 5%) by using Genotype-Tissue expression (GTex) Project data.

2023-04-19

The cover of the journal Genome Research highlights a YCU paper on tandem repeats that regulate gene splicing!

A research group led by Assistant Professor Kohei Hamanaka and Professor Naomichi Matsumoto of the Department of Human Genetics in the Graduate School of Medicine has succeeded in genome-wide identification of tandem repeats that regulate gene splicing,

2023-04-11

Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study

Objective: Despite extensive vaccination campaigns to combat the coronavirus disease (COVID-19) pandemic, variants of concern, particularly the Omicron variant (B.1.1.529 or BA.1), may escape the antibodies elicited by vaccination against SARS-CoV-2. Therefore, this study aimed to evaluate 50% neutralizing activity (NT50) against SARS-CoV-2 D614G, Delta, Omicron BA.1, and Omicron BA.2 and to develop prediction models to predict the risk of infection in a general population in Japan.